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Infections that result in natural or manmade spread of lethal biological agents are a
concern and require national and focused preparedness. In this manuscript, as part of
an early diagnostics and pathogen treatment strategy, we have focused on extracellular
vesicles (EVs) that arise following infections. Although the field of biodefense does not
currently have a rich resource in EVs literature, none the less, similar pathogens belonging
to the more classical emerging and non-emerging diseases have been studied in their
EV/exosomal contents and function. These exosomes are formed in late endosomes and
released from the cell membrane in almost every cell type in vivo. These vesicles contain
proteins, RNA, and lipids from the cells they originate from and function in development,
signal transduction, cell survival, and transfer of infectious material. The current review
focuses on how different forms of infection exploit the exosomal pathway and how
exosomes can be exploited artificially to treat infection and disease and potentially also
be used as a source of vaccine. Virally-infected cells can secrete viral as well as cellular
proteins and RNA in exosomes, allowing viruses to cause latent infection and spread of
miRNA to nearby cells prior to a subsequent infection. In addition to virally-infected host
cells, bacteria, protozoa, and fungi can all release small vesicles that contain pathogen-
associated molecular patterns, regulating the neighboring uninfected cells. Examples of
exosomes from both virally and bacterially infected cells point toward a re-programming
network of pathways in the recipient cells. Finally, many of these exosomes contain
cytokines andmiRNAs that in turn can effect gene expression in the recipient cells through
the classical toll-like receptor and NFkB pathway. Therefore, although exosomes do not
replicate as an independent entity, they however facilitate movement of infectious material
through tissues and may be the cause of many pathologies seen in infected hosts.
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EXTRACELLULAR MICROVESICLES
Small membrane bound vesicles secreted by cells can be detected using electron microscopy
(Delabranch et al., 2012). These extracellular vesicles (EVs) are released by all eukaryotic cells studied
to date as evident from both in vitro as well as in vivo studies. They are implicated to have roles in
cell-cell communication through protein and nucleic acid transfer, but also in carrying biomarkers
of disease (Fleming et al., 2014). The EV proteome, lipidome and mRNA/miRNAome represent
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TABLE 1 | Types and sizes of membrane vesicles.
Type of membrane vesicle Size Marker Reference
Microparticles 50–2000 nm VCAMP3, ARF6 Akers et al. (2013), Ghossoub et al. (2014), Kalasin and Santore
(2015)
Retrovirus-like particles (RLPs) 75–100 nm Gag Roberts et al. (2012), Akers et al. (2013)
Apoptotic bodies 500–4000 nm Thrombospondin, C3b, Annexin V Flügel-Koch et al. (2002), Akers et al. (2013), Cheung et al. (2015),
Roy et al. (2015)
Bacterial extracellular vesicles 10–300 nm PAMPs Bhatnagar et al. (2007), MacDonald and Kuehn (2012), Brown
et al. (2014), Fleming et al. (2014)
Exosomes 30–100 nm Transferrin, CD9, CD63, CD81, TSG101, Alix Schorey and Bhatnagar (2008), Subra et al. (2010), Delabranch
et al. (2012), Akers et al. (2013), Ghossoub et al. (2014), Raimondo
et al. (2015)
a snapshot in time of the cell status at themoment of release. These
EVs can carry bioreactive macromolecules such as nucleic acids,
proteins, and lipids, and thereforemay contribute to pathogenesis.
Types of Microvesicles
Various small vesicles, discovered in the 1960s, were originally
considered to be small platelets less than 1 mm wide (Delabranch
et al., 2012). There are several types of these extracellular
microvesicles, many of which are discussed in this review.
Microparticles are formed by ectocytosis, budding of the cell
membrane (Delabranch et al., 2012; Lagana et al., 2013), and
are generally 50–2000 nm (Akers et al., 2013). Retrovirus-like
particles (RLPs) are 90–100 nm and non-infectious, and they are
released from cells after a viral infection. Apoptotic bodies are the
largest group of microvesicles, 500–4000 nm, but smaller vesicles
are also formed when a cell undergoes apoptosis, 50–500 nm. The
different types of microvesicles are differentiated by their cellular
origin and not so much by size since their sizes tend to overlap.
The word “exosome” was coined byDr. Rose Johnstone because
they seemed to undergo “reverse endocytosis” (Johnstone et al.,
1987; Akers et al., 2013). Exosomes are defined as membrane-
bound vesicles formed within late endosomes and secreted from
the cell (Delabranch et al., 2012; Akers et al., 2013; Lagana et al.,
2013). Exosomes are usually 30–100 nm in length and contain
both functional and as yet undefined proteins andRNAs. Bacterial
cells also secrete vesicles, typically in the range of 10–300 nm in
diameter (MacDonald and Kuehn, 2012), and are often induced
under conditions of membrane stress. Vesicles that take in outside
material through macropinocytosis and enter the endosomal
pathway are different and called intraluminal vesicles (ILVs).
Most of these types of vesicles are formed by clathrin at the cell
membrane (Nour and Modis, 2014). Table 1 shows a list of the
types of EVs discussed, their sizes, and their protein markers.
Intraluminal Membrane Vesicles
Intraluminal vesicles are part of the endosomal pathway. They
take in components of the cellular membrane and recycle
biological material in a process called “back-fusion” (Nour and
Modis, 2014). Several viruses can use back-fusion as a route to
infecting cells, as the ILVs can take the virus particles straight
to the nucleus (Lagana et al., 2013; Nour and Modis, 2014).
The first virus to be discovered using back fusion as a delivery
method into the cytosol is the vesicular stomatitis virus (Nour and
Modis, 2014). Back fusion is most beneficial to DNA viruses that
require entry into the nucleus in order to replicate, though there
is evidence that some members of Flavivirus genus also use this
pathway to infect cells. Bacillus anthracis also utilizes back-fusion
as a means of delivering toxins into the recipient cells (Nour and
Modis, 2014).
Bacterial Membrane Vesicles
Similar to eukaryotic cells, bacteria also make and release
membrane vesicles. Gram-negative bacteria commonly are found
to produce vesicles, called outer-membrane vesicles that derive
from “blebbing” of the outer membrane, and forming vesicles that
can contain proteins, membrane components and occasionally
nucleic acids. Of the gram-negative bacteria that produce these
vesicles, many are pathogenic (Kadurugamuwa and Beveridge,
1999; Pierson et al., 2011; Nieves et al., 2014) and can have
toxic effects on host cells (Pierson et al., 2011), or can deliver
antigens and thus act as a potential vaccine (Pierson et al., 2011;
Nieves et al., 2014). Recently, gram-positive bacteria have also
been observed to produce vesicles (Brown et al., 2014), although
the mechanism may be different compared to gram-negative
organisms (Haurat et al., 2014). These bacterial vesicles may
have roles in both intra-species and inter-species communications
(Berleman and Auer, 2013), as well as potential inter-kingdom
interaction with the host (Kulp and Kuehn, 2010; Pierson
et al., 2011). Finally, these vesicles provide a new approach for
development of non-live vaccines, and for instance have been
successfully used in a New Zealand study with children infected
with Neisseria meningitidis (Wong et al., 2009).
Purification Methods
Whether they will be used as therapeutic agents or for research
purposes, it is necessary to purify exosomes using precise and
reproducible techniques (Thery et al., 2006). Exosomes are present
in low concentrations in extracellular fluids. Purification begins
with large volumes of cell-free exosome-containing fluids to
which increasing centrifugal forces are applied (Akers et al.,
2013). The ensuing pellet is then further purified over a sucrose
gradient and then immunoprecipitated using antibodies to known
exosomal markers, as viruses may co-purify with the exosomal
prep obtained from the gradient (Delabranch et al., 2012; Akers
et al., 2013; Figure 1). For in vitro analysis, many novel approaches
can be used prior to the centrifugation step. For instance the
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FIGURE 1 | Purification of exosomes using centrifugation or affinity beads. (A) An overview of a generalized procedure utilizing multistep centrifugation for
high volume of culture medium. A culture of infected cell supernatants (100 ml grown in exosome free media) is centrifuged at multiple speeds and for varying
times. The samples are next filtered to remove large debris including dead cells. After the final ultracentrifugation, the sample represents partially purified exosomes
(80%). Exosomes can be further purified using sucrose density or OptiPrep gradient (>95%). The x-axis represents % iodixanol in OptiPrep gradients. These
fractions can then be further purified with magnetic beads coated with antibodies to exosomal proteins such as C63 [usually present in higher amounts from RNA
virus infected cells such as HIV, HTLV-1, RVFV and Ebola]. (B) An overview of low volume purification with Nanotrap particles to separate exosomes from the virus
particles. Nano-captured exosomes can be used for PCR analysis (modified from Sampey et al., 2014).
analysis of secretory proteins from the cell line HepG2 and human
liver slices, utilized metabolic labeling of proteins which was
carried out for brief time periods, followed by collection and
filtration of cell supernatants and subsequent protein precipitation
and analysis using sensitive biochemical methods (Zwickl et al.,
2005).
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Since the commonly used methods are time-consuming, many
colleagues in the field are actively working toward more time-
saving isolation methods. Kanwar et al. (2014) have developed
a three-step immunoaffinity method using a microvesicle-chip
coated with antibodies against CD63. Clayton et al. (2001) have
developed a similar technique using magnetic bead isolation.
The use of antibodies in both methods renders the isolated
exosomes non-functional. Therefore, such methods of exosomal
preparation may only be used in diagnostic testing and not so
much for functional studies of exosomes.Another novel technique
for detecting microvesicles is through mNMR (Akers et al., 2013).
It is more precise than western blotting and ELISA as it can
distinguish betweenmicrovesicles fromhealthy samples vs. cancer
samples. It would be interesting to utilize mNMR in diseases such
as viral and bacterial infections since they also secrete vesicles that
are smaller and have different membraneous composition.
To discriminate exosomes and other small extracellular
particles, including virions, Jaworski et al. (2014a,b) proposed
to apply innovative Nanotrap technique. Nanotrap particles are
a novel technology that can address most critical analytical
challenges for pathogen identification andmeasurement. They are
homogenous hydrogel particles of about 800 nm in size that have
a shell made of polymers ofN-isopropylacrylamide (NIPAm) and
co-monomers such as acrylic acid (AAc) and allylamine (AA)with
cross links of N,N0-methylenebisacrylamide (BIS; Luchini et al.,
2008, 2009). Charge-based affinity baits are also incorporated
into the shell of the particles (Luchini et al., 2009). The recently
performed screening of Nanotrap particles indicated that the
particles containing vinyl sulfonic acid (VSA) in shell were highly
efficient at capture of Rift Valley fever virus (RVFV; Shafagati
et al., 2013) andHIV-1 virions (Jaworski et al., 2014b), whereas the
Nanotrap particles comprised of a shell architecture without VSA
were able to selectively capture exosomes from both cell culture
media and serum (Jaworski et al., 2014b). The exact mechanism
of this binding is unknown, although the selective capturing of the
viral particles and exosomesmay be associated with their different
surface charge or various glycosylation of surface glycoproteins.
Biomarkers of Microvesicles
The microvesicle biomarkers that have been cataloged include
proteins, mRNA, miRNA, and lipids. Various databases provide
a rich resource for the study of exosome components. Recently,
there have been several new databases developed to collect the
proteomic data that has been generated through proteomics
analysis of exosomes. These databases include EVPedia (Kim
et al., 2013), Vesiclepedia (Kalra et al., 2012), and Exocarta
(Kalra et al., 2012) among others. EVPedia has cataloged almost
50,000 proteins found in exosomes, more than 164,000 mRNAs,
and 12,000 miRNAs in various types of membrane vesicles.
Vesiclepedia has collected data from more than 350 different
studies. When examining these databases, there appears to be
few common proteins identified in these exosomes including the
exosome marker proteins Alix, CD63, CD81, CD9 (Schorey and
Bhatnagar, 2008), transferrin, and TSG101 (Akers et al., 2013;
Table 1). Although most of the published literature relies on
these proteins, there may be varying levels of certain markers
including TSG101, Alix, and CD63 following an infection.
Finally, each of the different types of microvesicles have certain
proteins and molecules that can be used as specific markers,
including thrombospondin, C3b, and Annexin V (for detection
of apoptotic bodies), as well as VCAMP3 and ARF6 (for detection
of microparticles; Akers et al., 2013). Overall, more than 52,000
proteins have been observed in microvesicles, 165,000 mRNAs,
13,000 miRNAs, and 350 different lipid species across the
multiple databases.
Nucleic Acid Component of Exosomes
Recently, miRNAs have been found outside of cells (Chen et al.,
2013; Lagana et al., 2013), circulating in serum and saliva, and
can be associated with microvesicles and exosomes (Gallo et al.,
2012). Some cell types are able to transcribe miRNAs for the
purpose of secretion through exosomes, which can then be used
to show phenotypic changes in recipient cells (Lagana et al., 2013).
The gold standard technique for analyzing circulating miRNAs
within exosomes and EVs from serum or plasma is qRT-PCR
(Moldovan et al., 2013). Exosome-centric studies of mRNA and
miRNA have led to the “Trojan Horse” hypothesis, as a potential
new method of genetic exchange between infected cells and
uninfected neighbor cells (Gould et al., 2003; Valadi et al., 2007).
miRandola andmiRiam are two programs available to predict and
evaluate miRNA in the circulation and from specific pathogens;
RepTar, ViTa, and vHoT are a few databases containing miRNA
information and predictions (Lagana et al., 2013). These are used
to determine what kind of an effect, if any, that a viral genome will
have on target cells (Lagana et al., 2013).
A virally-infected cell can secrete cellular and viral miRNA
via exosomes (Pegtel et al., 2010). Viral infection may affect
the composition of cellular miRNAs that are secreted by the
infected cell, and thus indirectly alter cell–cell communication
(Wurdinger et al., 2012). For instance, DNA and RNA viruses
mediate carcinogenesis via their encoded miRNAs (Verweij et al.,
2013). HIV-1 has at least two known miRNAs, one from TAR
element and the other called hiv1-mir-H1, which causes host cells
to undergo apoptosis (Lagana et al., 2013). Most of the viruses
that codemiRNAs areDNAviruses,mainly herpesviruses (Lagana
et al., 2013).
Exosome Lipids
Microvesicles are secreted as a result of signal transduction.
An influx of calcium activates two phospholipid transporters,
scramblase and floppase, which send phosphatidylserine to the
outer leaflet of the membrane where the microvesicle will bud
(Subra et al., 2010;Delabranch et al., 2012;Nour andModis, 2014).
The lipid composition of the vesicles differ from that of the parent
cell (Delabranch et al., 2012). Some viruses, such as Flavivirus,
can cause calcium to flow into the host cell (Nour and Modis,
2014). Most microvesicles have receptors and adhesion molecules
to signal target cells (Delabranch et al., 2012), and can transfer
these signals either via surface receptors or by endocytosis of the
vesicle by the target cell (Nour and Modis, 2014). One example is
tissue factor being brought to neutrophils and platelets. Exosomes
can interact with CD91 and Tim4when attaching to recipient cells
(Subra et al., 2010).
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Pathogens Use Exosomes for Their
Immediate Spread
Pathogens use exosomes to spread infection and to avoid the host
immune system (Delabranch et al., 2012; Lagana et al., 2013).
Viral infections can enter the latent phase using exosomes to safely
spread theirmiRNAs, undetectable to the immune system (Lagana
et al., 2013). The virus can hide in a few cells, slowly causing
neighboring cells to becomemore vulnerable to infection through
the miRNAs, until a signal triggers the virus to replicate again
and thus cause a rapid infection. It is not yet fully understood
how the viruses use microvesicles to avoid detection by the
immune system. It is thought that the immune system cannot
detect miRNAs of non-host origin, allowing the virus to spread
rapidly when using exosomes to transport viral miRNAs (Lagana
et al., 2013). For instance, the Chagas parasite transmits exosomes
into the host’s bloodstream to deactivate C3 convertase of the
complement pathway (Delabranch et al., 2012); and hepatitis C
infected cells effectively utilize exosomes to infect other cells,
where exosomes are not recognized by the host innate or acquired
immune responses (Nour and Modis, 2014).
Exosomes and the Immune System
The immune system uses toll-like receptors (TLRs) to recognize
pathogenic foreign nucleic acid (Chen et al., 2013). When
triggered, TLRs can cause a cell to release cytokines to attract
phagocytes to the location. TLR3 (Bai et al., 2014; Jiménez-
Sousa et al., 2015), TLR7 (Cohen et al., 2015), TLR8 (Cohen
et al., 2015), and TLR9 all are capable of binding to viral
dsRNA and ssRNA as well as viral and bacterial DNA (Chen
et al., 2013; Ishii et al., 2014). TLR8, more specifically, has
been shown to bind to ssRNA including HIV-1 genomic RNA
(Cohen et al., 2015). MiRNAs have recently been found to bind
to TLRs as well. TLR8 on macrophages can bind to miR-21
and miR-29a that are released from tumors, and thus cause
proinflammatory cytokine release from these cells. TLR7 can
bind to let-7b on neurons, leading to neurodegeneration in vitro
and in vivo (Winkler et al., 2014). These TLRs bind to GU-
rich regions of the miRNA, but the exact mechanism for the
interaction is currently unknown (Chen et al., 2013). TLRs of
dendritic cells (DCs), T cells, and macrophages activate these
cells when they come into contact with exosomes containing viral
miRNA (Chen et al., 2013; Nour and Modis, 2014). This may
contribute to novel vaccine methods to target exosomes where
antibodies may be ineffective (Lagana et al., 2013; Nour and
Modis, 2014).
Exosomes can also carry MHC class I and MHC class II
molecules and cause immunosuppression (Yang et al., 2012b).
Exosomes, especially from DC, have been shown to reduce
inflammation in mice due to IL-10, B7, and MHC class II.
Exosomes from plasma inmice can contain other proteinmarkers
such as CD71, FasL (also aids in suppressing inflammation), and
CD86 (Yang and Robbins, 2012). Exosomes from tumor cells
can contain transforming growth factor-b (TGF-b) on the lipid
surface to suppress T cells (Tran et al., 2015). Many cytokines
in macrophage-derived exosomes, such as CCL3, CCL4, CCL5,
TNFa, G-CSF, CSCL2, and IL-1RA, cause immune stimulation
in target cells. Pathogen-associated molecular patterns (PAMPs)
are also packaged into the exosomes from bacterially-infected
cells to cause a faster immune response (McDonald et al., 2014).
Exosomes from B cells can contain LAMP-1, CD20, BCR, various
tetraspanins, as well as heat shock proteins (Gehrmann et al.,
2014). Overall, immunoregulatory molecules incorporated into
the exosomes may cause both immuno-suppressive and immuno-
activation effects depending on their composition and cellular
source of the exosomes.
CD4+ Cells
T helper cells that express the CD4 glycoprotein on their surface
are also known as CD4+ T cells. Activation of CD4+ T cells
occurs when they are presented with peptide antigens complexed
to MHC class II molecules. It was thought that such presentation
occurred when peptides are expressed on the surface of antigen-
presenting cells (APCs) such as DCs. However, evidence is
accumulating to show that even exosomes secreted by DCs induce
stimulation of CD4+ T cells in vivo and in vitro (Thery et al.,
2002; Matsumoto et al., 2004; Hao et al., 2007). Activated CD4+
T cells release exosomes that contain T cell receptors (TCRs)
on their surface that stimulate exosome release from activated B
cells (Choudhuri et al., 2014). In turn, B-cell-released exosomes
can directly stimulate primed (but not naïve) CD4+ T cells, to
create a feedback loop in the process of T cell/B cell collaboration
(Muntasell et al., 2007).
Furthermore, secretion of exosomes from CD4+ T cells as
well as other immune cells also occurs constitutively. Secretion
of cytokines and their receptors, as well as other protective
factors occurs via exosomes. Documented cytokines and their
receptors include tumor necrosis factor-a (TNFa), TNFaR, TGF-
b, interleukin-1b (IL-1b), IL-18, IL-32, anddeath receptors ligands
such as FASL or TNF-related apoptosis-inducing ligand (TRAIL;
Gutierrez-Vazquez et al., 2013). For example, chicken biliary
exosomes possess the capacity to influence the immune responses
of lymphocytes. Specifically, they promote the proliferation of
CD4+ and CD8+ T cells and monocytes from liver and inhibit
the oncogenic retrovirus, avian leukosis virus subgroup J, from
replicating in vitro (Wang et al., 2014). The converse also occurs
where CD4+ T cell proliferation and cytokine secretion can
be suppressed by transforming miRNAs from exosomes derived
from T-reg cells (Okoye et al., 2014).
Exosomes secreted by CD4+ T cells protect uninfected cells
from viral infection and also protect them from reactivation of
viral elements contained in exosomes. The key factor within
exosomes mediating viral deactivation may be the nucleic acid
editing APOBEC3 (A3) family of cellular cytidine deaminases
(Khatua et al., 2009). This family of cytidine deaminase enzymes
is known to provide protection against reactivation of Alu and
L1 retrotransposons. Khatua et al. (2010) have demonstrated
that exosomal A3G and A3F proteins and A3G mRNA secreted
by CD4+H9 T cells and mature monocyte-derived DCs were
functional in vitro to inhibit L1 and Alu retrotransposition.
Collectively, exosomes encapsulate factors (proteins and RNA)
that are mostly functional in protecting neighboring cells against
reactivation of viral elements by forming a secondary line of
defense following viral entry.
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Exosomes as Vaccines
Exosomes have been shown to have the potential to be used
as vaccines. For instance, Streptococcus pneumonia-infected
dendritic-cell derived exosomes contain capsular polysaccharide
(capsular antigen) and protect mice against S. pneumonia
infection (Colino and Snapper, 2007). Toxoplasma gondii infected
DC-derived exosomes were used to protect against T. gondii
infection in mice (Beauvillain et al., 2009). DC derived exosomes
from cells infected with the parasite Eimeria were found to
convey protection in a poultry model (del Cacho et al., 2013).
DC derived exosomes were also found to confer protective
immunity against Leishmania in mice (Schnitzer et al., 2010).
Exosomes from B cells infected by Epstein-Barr virus (EBV)
protect uninfected B-cells from EBV infection (Vallhov et al.,
2010), and exosomes from Leishmania-infected macrophages
confer protection to naïve macrophages (Cronemberger-Andrade
et al., 2014). Khatua et al. (2009) have demonstrated that exosomes
containingA3Gprovide uninfected T cells resistance to continued
HIV-1 proliferation. The prevalence of DC and macrophage-
derived exosomes in these examples reveals an important and
direct interaction of exosomeswith the immune system. Therefore
DCderived exosomes are amajor source of potential vaccines (Pitt
et al., 2014).
As with any vaccine, there are limitations to using exosomes.
One limitation is that they are heterogeneous, containing various
proteins and materials from cells, making the exosomes harder
to control than liposomes. Currently, liposomes are used as
drug- and antigen-delivery vessels because they are protective
of the cargo, can carry hydrophobic and hydrophilic molecules,
and they can cross the plasma membrane into cells easily (Lai
et al., 2013). Liposomes are a useful tool, but they can prove
toxic in some instances (Lai et al., 2013). Liposomes are easy
to synthesize and to package the immunogens and adjuvants,
whereas exosomes have proven to be much more difficult for
insertion of desired components (Lai et al., 2013). It is important
to note that exosomes injected into a patient must compete
with natural exosomes in the body to have the desired effects.
Manipulating the lipid composition and ligands/receptors on
exosomes can decrease the uptake of exosomes from specific cell
types. Recent studies have shown that exosomes from DCs can
be blocked from entering bone marrow derived dendritic cells
(BMDC) by coating the exosome’s CD11a, CD54, CD9, or CD81
with antibodies. Exosomes can also be blocked by binding of
competitive ligands to the cell receptors (Marcus and Leonard,
2013).
Exosomes as Therapeutics
Biotherapeutics range from small peptides to siRNA molecules.
In the laboratory, they are highly efficacious. In the clinic, they
have shown their limitations with respect to lower half-lives,
off-target effects and inability to cross the blood–brain barrier.
Exosomes can help overcome these drawbacks. Since exosomes
are natural agents of intercellular delivery, they can be exploited
to become carriers of engineered therapeutics (Kooijmans et al.,
2012). Some drugs can be inserted into purified exosomes in vitro,
or incorporated into exosomes as they aremade in vivo, by tagging
the drugs for exosomal targeting (Lai et al., 2013). Exosomes that
can target certain tissue types and can protect cargo from the
immune system are more ideal than liposomes, as they also have
a longer half-life (Lai et al., 2013).
Sun et al. (2010) provided the first proof-of-concept for
biotechnological exploitation of exosomes. Curcumin was mixed
with exosomes to enhance the bioavailability, stability, and
solubility (Sun et al., 2010). Mixing with exosomes improved
the anti-inflammatory activity compared with curcumin alone in
an in vivo lipopolysaccharide-induced septic shock model (Sun
et al., 2010). A subsequent study by (Zhuang et al., 2011) went
a step further by utilizing exosomes to deliver anti-inflammatory
drugs to the brain through a non-invasive intranasal route. These
exosomes were designed to enclose either curcumin or a Stat3-
inhibitor; both molecules were able to bypass the blood–brain
barrier.
Exosomes can target to specific tissue types naturally and
artificially. Astrocytes can release miR-29b in exosomes after
the cells are given morphine and Tat from HIV-1. Cultured
neurons treated with these exosomes displayed miR-29b in their
cytoplasm within 4 h. This miRNA targets the gene PDGF-
B and causes neuronal death. It is well known that astrocytes
communicate with neurons, and this study demonstrated first that
the exosomes play a key role in this communication (Hu et al.,
2012). Exosomes can participate in neuron synapses to promote
survival and growth of target neurons. Another study focused on
analyzing the effects of exosome-incorporated siRNA, showing
that injections of the vesicles into blood of laboratory animals
can in turn stop gene expression in CNS (Gupta and Pulliam,
2014). The exosomes derived from bone marrow stromal cells are
important for communication with multiple myeloma cells, and
promote growth, migration, and drug resistance. These exosomes
transfer such cytokines as IL-6, MCP-1, and IL-13 (Wang et al.,
2014).
Experiments by Alvarez-Erviti et al. (2011) included a homing
mechanism to their exosomes so as to specifically target a
certain tissue type where the exosomes would unload their cargo.
Exosomes derived from immature DCs were used for delivering
exogenous siRNA in vitro as well as in vivo by, i.v., injection
to target the brain. Targeting was achieved by engineering the
exosomal surface protein lamp2b to also display a targeting
peptide derived from the rabies virus glycoprotein (RVG). This
peptide is known to bind nicotinic acetylcholine receptor present
on neurons and the vascular endothelium of the blood–brain
barrier. The method proved efficacious with up to 60% RNA
and protein knockdown predominantly in the neurons of the
midbrain, cortex and striatum, and this method was neither toxic
nor immunogenic. Taken together, these examples demonstrate
the potential of exosomes to be used for targeted delivery of
multiple therapeutics to different tissues and cell types.
INFECTIONS AND EXOSOMES
Fungi, bacteria, protozoa, and viruses all secrete some form
of microvesicle (Delabranch et al., 2012). For instance, viral
infections cause exosome formation and secretion from infected
host cells. HIV-1 infected cells releases negative factor (Nef)
protein in exosomes to alter dynamics of signal transduction
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FIGURE 2 | Exosomes from virally-infected cells have various specific effects on target cells. Exosomes from HIV-1- and HTLV-1-infected cells contain viral
and cellular proteins and double- and single-stranded RNA. Within a target cell, the proteins decrease apoptosis and cell migration, whereas RNA increases gene
expression in the nucleus in order to promote infection. Exosomes from HCV-infected cells contain non-enveloped virions (both mature and immature). These virions
can enter a target cell using exosomes and replicate on the ER membranes. Exosomes from HHV-6-infected cells contain mature virions that spread infection faster
through the use of exosomes. Exosomes from EBV-infected cells contain viral DNA and viral and cellular proteins that increase cytokine and chemokine production in
target cells (through innate immune molecules), and thus increase cytokine expression and inflammation. Exosomes from KSHV-infected cells contain viral miRNAs
and proteins that increase glycolysis and gene expression in target cells.
in host recipient cell (Delabranch et al., 2012; Lagana et al.,
2013). Hepatitis C and Hepatitis A infected cells use exosomes
as a vesicle to infect new cells with viral RNA and proteins.
Some non-enveloped viruses, such as Hepatitis A, use the host
cell’s endosomes to envelope the virus (Nour and Modis, 2014).
Figure 2 shows some effects of exosomes from virally-infected
cells on uninfected target cells. Finally, non-nucleic acid infections
material (such as prions) have been identified in exosomes which
may contribute to pathogenesis (Fevrier et al., 2004; Leblanc et al.,
2006; Saá et al., 2014). Cells infected with bacteria can release
exosomes that presents PAMPs to immune cells (Bhatnagar
et al., 2007). Protozoan parasites also have been shown to
release exosomes with protozoan molecules into the bloodstream
(Beauvillain et al., 2009). Therefore, in the following section, we
will describe some of the highlights from the literature on how
exosomes containing viral, bacterial, and other agents contribute
to pathogenesis.
DNA Viruses
Epstein-Barr Virus
The EBV is a large DNA virus associated with B-cell lymphomas
and carcinomas in tongue, nasopharynx, and stomach. The
virus is found in a latent stage in both lymphomas and
carcinomas (Morales-Sanchez and Fuentes-Panana, 2014). The
presence of oncoproteins and viral miRNAs in exosomes
from EBV-infected cells gives credence to the fact that virus-
infected cells use the exosomal pathway to regulate gene
expression in the surrounding tissue to avert destruction by
the immune system. Evidence is accumulating to show that
inhibitory exosomes promote immune evasion and progression
of EBV associated tumors such as Hodgkin’s disease (HD;
Gandhi et al., 2007) and nasopharyngeal carcinoma (NPC; Li
et al., 2007). Besides EBV, other DNA and RNA viruses also
mediate carcinogenesis via their encoded miRNAs (Verweij et al.,
2013).
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Meckes et al. (2013) studied the specific effects of the oncogenic
herpesviruses, EBV and Kaposi sarcoma-associated virus, on
the proteomes of B-cell exosomes using global quantitative
proteomics. They studied exosomes purified from 11 B-cell lines
that were uninfected, infected with EBV orwith Kaposi’s sarcoma-
associated herpesvirus (KSHV), or infected with both viruses.
Using mass spectrometry, 871 proteins were identified, of which
360were unique to the viral exosomes. Analysis by 2Ddifference
gel electrophoresis and spectral counting indicates that the viruses
greatly impact the protein content of exosomes with common
and distinct changes induced by both viruses. Of the proteins
found in samples from EBV and KSHV exosomes, several have
similar functions associated with cancer, predicting disorders and
disease, cell survival or cell death, and signaling of EIF2 in the
canonical pathway. It is likely that these alterations in exosome
content modulate the tumor environment, potentially to enhance
viral infection and promote tumorigenesis (Meckes et al., 2013).
EBV-transformed cells express at least 44 mature viral miRNAs
that target viral and cellular genes along with deregulating the
miRNA profile of the host cell. MiRNA profiling showed that
2% of the miRNAs of diffuse large B-cell lymphoma (DLBCL)
and nasal NK/T-cell lymphoma (NKTL) are derived from the
virus, while 20% of the total miRNA in NPC are viral miRNAs
(Barth et al., 2011). The miRNAs inhibit the apoptotic response
of the infected cell as a means to establish a latent infection.
Other studies have corroborated the observation that besides
oncoproteins, miRNA encoded by EBV may also contribute to
EBV-mediated transformation of B-cells (Feederle et al., 2011;
Vereide et al., 2014).
Biogenesis and uptake of exosomes
Epstein-Barr virus exploits the endosomal–exosomal pathway
to enclose both EBV-associated and cellular macromolecules in
the endosomes. MiRNAs secretion via exosomes begins with
their assembly with RISC at endosomes (Pegtel et al., 2011).
Thus miRNA function, mRNA stability and exosome-mediated
intercellular communication converge at the level of endosomes
(Verweij et al., 2011).
CD63, found in exosomes, is a tetraspanin protein that
assembles in small membranous platforms and guides
intracellular trafficking of associated-partners. LMP1 co-opts the
physiological role of CD63 in human B cells for its own benefit.
Knock-down of CD63 by short hairpin RNAs against CD63 led
to sequestering of LMP1 protein in intracellular compartments;
so, LMP1 may associate with CD63 prior to reaching the plasma
membrane (Verweij et al., 2011).
Released exosomes act on neighboring as well as distant
cells by circulating through plasma. They are internalized by
recipient cells via caveolae-dependent endocytosis and eventually
traffic through an endosomal pathway (Nanbo et al., 2013).
The transferred molecules are functional in recipient cells. For
example LMP1 released in this manner causes the upregulation
of ICAM-1 in recipient cells (Nanbo et al., 2013). These results are
in line with a previous publication showing that LMP1 induces the
expression of cellular proteins, including ICAM-1 in EBV-infected
cells (Wang et al., 1990). Internalized exosomes lead to isolated
B-cell’s proliferation, induction of activation-induced cytidine
deaminase, and the production of circle and germline transcripts
for IgG1 (Gutzeit et al., 2014). In this manner, some or all of the
exosomal factors may be at play in preventing uninfected B cells
from being infected by EBV, as demonstrated for B cells isolated
from umbilical cord blood (Vallhov et al., 2010). EBV studies
suggest that exosomes derived from different cells types have
different mechanisms for targeting recipient cells. For example,
exosomes derived from EBV-transformed B cell lines target B-
cells; this targeting can be blocked efficiently by anti-CD21 or
anti-gp350, molecules present on B-cells and exosomes derived
from EBV infected cells respectively (Vallhov et al., 2010).
EBV proteins in exosomes
EBV-infected B cells secrete exosomes containing: EBV-encoded
miRNAs (Pegtel et al., 2010), mRNA for EBNA (Canitano et al.,
2013), small non-coding RNA complexed with proteins (Ahmed
et al., 2014) and various proteins of viral origin such as LMP1
(Meckes et al., 2010; Yoshizaki et al., 2013), and host origin such
as galectin-9 (Gourzones et al., 2012). Host originating proteins
include pro-tumorigenic molecules including HIF1a (Aga et al.,
2014).
LMP1 is one of the best recognized oncogenic viral protein.
It is a signaling protein that imitates a constitutively active TNF
receptor. In the soft agar transformation and transwell metastasis
assays, LMP1 enhances cell growth and migration through
activation of phosphatidylinositol 3-kinase (PI3K)/Akt and NFkB
signaling (Shair et al., 2009). LMP1 activates multiple distinct
signaling pathways (EGFR, STAT3, and ERK) via PKCd (Kung
et al., 2011). This activation is seen not only in EBV infected cells
but also in epithelial, endothelial, and fibroblast cells that receive
purified exosomes from EBV infected cells. Downstream effects
of this activation are expression of cytokines and chemokines
leading to inflammation. Preparations of exosomes containing
LMP1 were shown to inhibit the proliferation of peripheral blood
mononuclear cells. In EBV-associated tumors such as NPC and
HD, LMP1-containing exosomes may be taken up by infiltrating
T-lymphocytes, where LMP1 could exert its anti-proliferative
effect to allow the tumor cells to evade the immune system
(Flanagan et al., 2003). LMP1 induces secretion of exosomes
that contain fibroblast growth factor (FGF-2; Ceccarelli et al.,
2007). Secretion of angiogenic factors such as FGF-2 may be
responsible for the metastasis essential for tumor spread seen in
EBV-associated cancers.
Galectin-9 is a protein that specifically interacts with
membrane receptor Tim1 and induces apoptosis in T cells.
Conditioned media from EBV infected xenografts which were
either LMP1-positive or negative secreted exosomes containing
galectin-9. These exosomes could inhibit T-cell proliferation
assessed on peripheral blood mononuclear cells activated by
CD3/CD28 cross-linking (Keryer-Bibens et al., 2006).
Deoxyuridine triphosphatase (dUTPase) is an enzyme that
catalyzes hydrolysis of dUTP to deoxyuridylate and inorganic
pyrophosphate. Mice injected with purified EBV dUTPase show
inhibition of replication of mitogen-stimulated lymphocytes
(Padgett et al., 2004). Ariza et al. (2013) observed at least a 700-
fold enrichment of dUTPase activity in exosomal fractions when
compared to concentrated culture supernatants from chemically
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induced Raji cells, and they found a 4.8-fold increase in dUTPase
activity in exosomes derived from chemically induced Raji cells
relative to non-induced cells. EBV-encoded dUTPase secreted
in exosomes from chemically induced Raji cells induced the
secretion of cytokines and chemokines through TLR2 in human
primary recipient cells.
Elevated amounts of EGFR can be detected in NPC. EGFR
expression and secretion from the cell in exosomes correlates with
the levels of LMP1. In fact, LMP1 induces expression of EGFR
(Meckes et al., 2010). Interferon-inducible protein 16 (IFI16)
and cleaved caspase-1, IL-1b, IL-18, and IL-33 are all seen in
the exosomes from Raji cells and EBV-transformed cell lines
(Ansari et al., 2013). The expulsion of nuclear-resident protein
IFI16 via exosomes is critical to EBV’s escape of recognition by
the innate immune response since the protein functions as the
non-sequence-specific direct recognizer of the EBV genome.
Translational studies on EBV exosomes
Since the EBV proteins LMP1 and BARF1 are detected in serum
of EBV-infected patients, these proteins can serve as efficient
diagnostic markers for NPC (Houali et al., 2007). LMP1 has
greater potential for a biomarker than BARF1 has because LMP1
is found in exosomes that can easily be purified and provide a
natural mechanism for concentration of the protein. In patients
infected with EBV, EBV BART miRNAs are present in both
B-cell and non-B-cell fractions, but EBV DNA is restricted
to the circulating B-cell population, which suggests miRNA
can be transfered via exosomes in vivo (Pegtel et al., 2010).
Confirmation of this type of transfer came from studies by
Gourzones et al. (2010), who demonstrated that the sera of
NPC patients also contain BART miRNAs. Plasma samples
from NPC patients and mice xenografted with NPC tumors
also show presence of galectin-9-containing exosomes (Klibi
et al., 2009). Incorporation into exosomes protects galectin-9
against proteolytic cleavage, retaining its Tim-3-binding capacity.
In turn, these exosomes have been shown to induce massive
apoptosis in EBV-specific CD4+ cells used as a model of target
T cells.
EBV miRNA in exosomes
Pegtel et al. (2010) observed viral BHRF1 miRNAs in B95.8-
immortalized EBV-immortalized cells that are delivered
by exosomes to non-infected cells. The exosomes targeted
the CXCL11/ITAC gene in uninfected neighboring cells.
Gourzones et al. (2010) showed that EBV miR-BARTs present
in exosomes can be detected in the serum of mice xenografted
with human NPC cells. miR-BART15-3p was found highly
enriched in exosomes from an EBV-positive gastric cancer
cell line. miR-BART15-3p targets the apoptosis inhibitor
BRUCE to induce apoptosis in recipient cells. This shows
how, again, an exosomal component can provide a favorable
microenvironment for the growth of EBV-associated tumors
(Choi et al., 2013). However, not all EBV-encoded miRNA is
transferred via exosomes since high concentrations of the viral
microRNA BART17 have been detected outside of exosomes in
plasma samples from NPC patients (Gourzones et al., 2013).
Therefore exosomes have the potential to modulate immune
functions of neighboring cells to alter the microenvironment
and contribute to the pathophysiology of EBV-associated
diseases because of the secretion of oncogenic, anti-apoptotic
and pro-inflammatory molecules in exosomes from EBV
infected cells.
Herpesvirus
The role of protein transfer from intracellular compartments to
exosomes has also been studied in Herpes-simplex virus-1 (HSV-
1) infected cells. Temme et al. (2010), have shown that the HSV-
1 encoded glycoprotein B (gB) manipulates class II processing
pathway by perturbing endosomal sorting and trafficking ofHLA-
DR (DR) molecules. Co-staining of gB, DR, and CD63 suggested
that these markers are contained in enlarged vesicular structures
of endosomal origin, and intervention of gB in this route appears
to induce formation of enlarged vesicles. Interestingly, the human
herpes virus 6 (HHV-6) induces formation of multivesicular
bodies (MVBs; Mori et al., 2008). In ILVs contained in these
MVBs, HHV-6–derived glycoproteins B and M were detected.
HHV-6 uses the cellular exosomal pathway of the host cell for
exiting the cell.
An attractive target for viruses is the ubiquitin system, which
regulates intracellular sorting of proteins and their degradation.
Ubiquitination was reported to be a signal for sorting of ILV in
MVBs (Piper and Katzmann, 2007). Along these lines, Temme
et al. (2010), found ubiquitination of gB in immunoprecipitates
of the viral proteins from MJ-gB cells. Collectively, their
data suggests that cellular ubiquitination of gB correlates with
increased release of exosomal material further indicating that
exosomes can transfer MHCII/peptide complexes to other cell
types. The recipient cells then acquire the ability to present
specific antigen. It is conceivable that a transfer of gB or of
gB/DR complexes by exosomes from HSV-1–infected cells to
other cells may also modulate immune responses to the viral
antigens.
Enveloped virions are known to be released by the exosomal
pathway. Mori et al. (2008) have shown that HHV-6-infected
cells were larger than uninfected cells and contained many
newly formed MVB-like compartments, including small vesicles
that surround the Golgi apparatus. They also found that virus
budding at TGN associated membranes, which expressed CD63,
can incorporate adaptor protein (AP-1), TGN46, and CD63
into virions. Therefore, mature HHV-6 virions may be released
together with internal vesicles through MVBs by the cellular
exosomal pathway. Remarkably, the vacuoles that enwrapped
the mature virions contained clathrin-coated membrane domains
that frequently form a bud. This may be similar to human
cytomegalovirus (HCMV) infection, where EM analysis shows
viral particles withinMVBs and occasionally budding intoMVBs;
therefore, MVBs might also be the final budding site of HCMV
(Fraile-Ramos et al., 2002).
Finally, the role of MVBs may be that HHV-6 replicates more
efficiently after virus spreading by direct cell-to-cell contact than
after cell-free spread. It is conceivable that in T cells, the viral
glycoproteins and cellular proteins expressed on exosomes may
interact to form a “virological synapse” to promote the efficient
spreading of virus from infected to uninfected cells.
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Kaposi’s sarcoma-associated herpesvirus
There have been efforts to define not only contents of EBV and
KSHV exosomes but also their function in recipient cells. For
example, Meckes et al. (2013) showed that distinct viral-specific
effects from KSHV exosomes would affect cellular metabolism,
whereas EBV specific exosomes would activate cellular signaling
mediated through integrins, actin, interferons (IFN), and NFkB.
These findings suggested that both viruses affect exosome
content to modulate both cell death and protein synthesis.
KSHV recently has been shown to reprogram the host B-cell
metabolism, promoting glycolysis, and the exosomes produced
by the KSHV infected cells are highly enriched with proteins
from the glycolytic pathway. Overexpression of pyruvate kinase,
lactase dehydrogenase, or phosphoglucose isomerase increases
glycolysis, and thus exosomal transfer of these enzymes could
modulate metabolism in recipient cells. The KSHV exosomes
also include proteins involved in remodeling epithelial adherens
junctions, suggesting that these exosomes may modulate cell
anchorage or movement. Therefore, it is likely that these effects
contribute to viral persistence and pathogenesis.
Factors that could potentially act as a restriction factor in
the lytic replicative cycles can also be found in exosomes from
herpesvirus infections. For example, during primary KSHV
infection of endothelial cells, acting as a nuclear pattern
recognition receptor, gamma IFI16 colocalized with the KSHV
genome in the nuclei and interacted with apoptosis-associated
speck-like protein containing a CARD (ASC) and procaspase-1
to form a functional inflammasome (Singh et al., 2013). Release
of IFI16 in the exosomes derived from BCBL-1 cells further
suggested a higher-order complexity of viral regulation of host-
mediated responses. A recent report describes how IFI16 acts as
a restriction factor for HCMV replication (Gariano et al., 2012).
The authors demonstrate that small interfering RNA-mediated
silencing of IFI16 in human embryo lung fibroblasts (HELFs)
result in enhanced replication of HSV-1, HSV-2, and HCMV
(Gariano et al., 2012). Therefore IFI16 may be a novel restriction
factor in the lytic replicative cycles of herpesviruses that is present
in the nucleus to control viral DNA replication and also to be
secreted within exosomes to control latency.
Finally, exosomes from KSHV infected cells serve as a means
of intercellular communication with surrounding cells, and the
contents of exosomes can be shared between cells through the
mechanism of exosomal transfer. KSHV exosomes can deliver
functional miRNAs to recipient cells to downregulate expression
of target genes. In a recent study, Chugh et al. (2013) demonstrated
that exosomes from patient PEL fluid, the BCBL1 PEL cell line,
and a xenograftmousemodel of KS confer an enhancedmigration
phenotype to hTERT-HUVEC cells in vitro as well as in a scratch
assay. Their data implies that miRNAs specifically expressed
within exosomes aid in disease progression andmediate paracrine
effects, which are commonly seen inKSHV tumorigenesis (Chugh
et al., 2013).
RNA Viruses
HIV/HTLV Infection
Arenaccio et al. (2014) have shown that exosomes from HIV-
1-infected primary CD4+ T lymphocyte are able to activate
quiescent human primary CD4+ T lymphocytes, which can
then replicate HIV-1. Nef, ADAM17, and TNF-a were part of
the underlying mechanism. TNF-a release requires the activity
of protease ADAM17, also called TNF-a-converting enzyme
(TACE), which can be transferred/provided by exosomes. They
also found that resting CD4+ T lymphocytes challenged by
exosomes from HIV-1-infected cells release both TNF-a and
IL-2. TNF-a release peaked at 6 h after exosome challenge,
thereby remaining sustained within the 48 h of observation;
whereas the highest number of IL-2-producing cells was present
at the 48-h time point. These data suggested that the IL-2
release was a consequence of cellular activation induced by
the autocrine/paracrine stimulus of TNF-a. The data implied a
model where Nef expression was necessary to arm exosomes
with active ADAM17 in order to render resting bystander
lymphocytes permissive for HIV replication. This mechanism
would be particularly relevant in primary infection and would
explain the rapid spread of viral infection in organs including gut.
Similar to other pathogens, retroviruses hijack exosomal
proteins as well as other components to increase their spread
throughout the body. In addition to this benefit, the resulting
changes in recipient cells can be profound leading to disease
state and pathologies associated with an infection. To this
end, HIV-1 infected macrophages have been shown to have
increased number of exosomes and other vesicles secreted from
the cell (Kadiu and Gendelman, 2011a,b; Kadiu et al., 2011,
2012). Importantly, these exosomes have been shown to contain
various cytokines that induce migration and release of other
inflammatory cytokines from recipient cells leading to enhanced
HIV-1 infectivity. Moreover, some of the virions shed from
infected macrophages have been shown to be associated with
large aggregates of exosomes secreted from cells and resulting
entrapment of virions has demonstrated enhanced infectivity
toward target cells including T cells as compared to free purified
virions. Additionally, the proteomic analysis of the exosomes
from macrophages has identified proteins required for T cell
activation, antigen presentation, and chemotaxis. Similar to these
findings, we have also recently identified alteration of proteins
and cytokines packaged into exosomes from HTLV-infected cells
(Jaworski et al., 2014a). The release of these cytokines packaged
into exosomes from HTLV-infected cells can lead to enhanced
infectivity in recipient cells as well as neuroinflammation
associatedwithHAM/TSP pathology. Therefore, collectively these
data demonstrate multiple potential mechanisms where virally-
infected cells control exosome release to assist in viral spread and
induction of pathologies. These vesicles can in turn activate naïve
cells leading to better uptake of virus and cell to cell transmission
of viral particles through viral synapses.
In addition to changes in the composition of host proteins
both HIV and HTLV readily incorporate their own nucleic
acids and viral proteins into the exosomes. For instance, recent
development has shown that Tax of HTLV-1 is incorporated
into the exosomes, which are secreted from both cell lines and
primary cells infected with HTLV-1 (Jaworski et al., 2014a). The
release of Tax in these exosomes represents one mechanism
where HTLV-1 virus can induce deregulation of T cells as well as
increase in neuroinflammation observed in HAM/TSP patients.
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Additionally, while the overall mechanism of trafficking of viral
proteins in HTLV-1 is not well defined, on the other hand HIV-
1 exosomes incorporate Nef, which represents a well-defined
biochemical pathway of trafficking of proteins into microvesicles.
Beyond protein changes observed in the exosomes, there are
also small RNA molecules that are packaged and incorporated
into exosomes from infected cells. For instance, we have recently
found that a 52-base stem-and-loop structure called TAR
(viral transacting response element) transcribed from integrated
provirus is incorporated within exosomes from HIV-1 infected
cells. These TAR element is found not only in cell culture, but also
sera of patients on antiretroviral drugs as well as long-term non-
progressors (LNTPs; Narayanan et al., 2013). The concentration
of the TAR molecule in these vesicles are high enough that
simple PCR methods can be used to detect RNA from patient
sera (103–106 copies per ml). Furthermore, the TAR RNA was
found to be associated with components of themiRNAmachinery
which are involved in generation of specific 50 and 30 miRNAs.
Interestingly, the level of components of the miRNA machinery
incorporation into exosomes varies dramatically between HIV-
1 and HTLV infected exosomes. For instance, we have recently
found that in contrast to HIV-1 infected cells exosomes from
cell lines infected with HTLV-1 contain Tax protein but minimal
to no viral miRNA (Jaworski et al., 2014a). There is also an
increased level of Ago2 bound to cellular miRNAs suggesting that
HTLV-1 infected exosomes can rapidly control mRNA and their
subsequent inhibition in recipient cells.
We have also recently observed presence of full-length viral
RNA in the exosomes from HIV-infected cells when using
nanoparticle capture assays (described above). These exosomes
have minimal capacity for infection in recipient cells leading us to
believe that genomic RNAs that may be packages in the exosomes
(CD63 positive exosomes) are not infectious primarily due to lack
of all the components necessary for the reverse transcription step.
Collectively exosomes secreted from HIV-1 and HTLV-1 infected
cells allow activation of recipient cells and subsequent exposure to
the virus resulting in enhanced pathology.
Hepatitis C Virus
The hepatitis C virus (HCV) is a small enveloped virus with
positive-sense single-stranded RNA genome which belongs to
the family Flaviviridae (Cuthbert, 1990). This virus infects
hepatocytes where the viral RNA replicates in the cytoplasm
via the viral RNA-dependent RNA polymerase. This enzyme
produces a negative-strand RNA that serves as a template for
new positive-strand viral genomes that can then be translated
or packaged into the new viral particles. The virus replicates
on the membranes of endoplasmic reticulum (Dubuisson et al.,
2002). Nascent virus particles use the cellular secretory pathway
for budding and release. The progeny HCV particles consist of
a nucleocapsid containing the viral genome, enveloped by an
endoplasmic reticulum-derived lipid bilayer with viral envelope
glycoproteins (Catanese et al., 2013). However, the level of virion
production in HCV infected cells is very low; virions are unstable
and structurally irregular (Catanese et al., 2013). Recent studies
suggest that HCV virion assembly and release in hepatocytes
can be associated with the exosome secretory pathway (Tamai
et al., 2012). Thus, the assembly pathway engaged by this virus
leads to incorporation of whole virions or only nucleocapsids,
envelope proteins and replication-competent viral RNA into the
exosomes (Masciopinto et al., 2004; Ramakrishnaiah et al., 2013;
Bukong et al., 2014; Liu et al., 2014; Longatti et al., 2014).
Recent studies of Ramakrishnaiah et al. (2013) showed that apart
from classical transmission by free viral particles, HCV can be
transmitted by exosomes to naïve human hepatoma Huh7.5.1
cells and can establish a productive infection with efficiency
comparable to that established by free infectious particles. Because
of this transmission mechanism, the virus can evade humoral
immune responses (Bruggmann et al., 2008; Fafi-Kremer et al.,
2010). Analysis of the exosomes from HCV-infected hepatoma
cells revealed presence of full-length viral RNA along with
host-cell RNA molecules, including miR122 (Pan et al., 2012;
Bukong et al., 2014). Viral envelope E1 and E2 proteins were
shown to be unnecessary for the transmission of exosomes, albeit
incorporation of these glycoproteins into the exosomes led to
enhanced transmission (Ramakrishnaiah et al., 2013).
Later studies of Bukong et al. (2014) demonstrated the capacity
of the exosomes isolated from sera of chronic HCV infected
patients to mediate viral receptor-independent transmission of
HCV to naïve hepatocytes. The exosomes contained negative-
strand HCV RNA, indicating incorporation of replication
competent viral genome. The exosomes containing the HCV
genome also harbored miR-122, as well as Ago2 and HSP90
proteins. Earlier studies demonstrated that these components
may enhance HCV replication (Jopling et al., 2005; Henke et al.,
2008; Wilson et al., 2011). Consistent with recent reports, Ago2
and miR-122 can enhance HCV replication when bound to
the 50-UTR of HCV dsRNA (Wilson et al., 2011); miR-122 was
demonstrated to be present in exosomes isolated from both HCV
infectedHuh7.5 cells andHCV-infected individuals. Bukong et al.
(2014) found that Ago2 is associated with miR-122, positive sense
HCV RNA and, in some cases, negative sense HCV RNA as well.
Using co-immunoprecipitation, they confirmed that HSP90 and
Ago2 form complexes within the HCV containing exosomes,
likely to provide further stabilization of the HCVRNA-replication
complex (Bukong et al., 2014). This shows that miR-122 in
the exosomes can provide advantages for HCV transmission
(Bukong et al., 2014). Taken together, existing data indicate that
the exosomes from HCV infected cell line, as well as serum
exosomes from some HCV infected treatment-naïve patients
contain positive sense viral RNA and are able to transmit active
HCV infection.
Bacterial Pathogens
Pathogen-associated molecular patterns have been identified
on exosomes in multiple studies (Fleming et al., 2014). These
molecules are frequently lipid- and/or carbohydrate-containing
molecules. For example, mycobacterial components such as
lipoarabinomannan (LAM) as well asmycobacterial proteins were
found in exosomes (Beatty et al., 2000) and these exosomes
can bind to normal, uninfected cells (Beatty et al., 2000, 2001;
Bhatnagar et al., 2007), possibly by binding to PAMP-receptors
such as toll like receptors (O’Neill and Quah, 2008). Exosomes
containing certain PAMPs are also capable of stimulating
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a proinflammatory response in uninfected cells (Bhatnagar
and Schorey, 2007; Colino and Snapper, 2007; Singh et al.,
2012). For example, exosomes from Salmonella typhimurium-
infected macrophages, which were found to contain Salmonella
lipopolysaccharide, stimulated proinflammatory responses both
in cell-based assays and in mice (Bhatnagar et al., 2007).
Mycobacterium tuberculosis-infected macrophages also had this
effect (Bhatnagar and Schorey, 2007) while simultaneously
triggering the downregulation of a number of IFN-g inducible
genes in naïve cells including inhibition of inducible expression
of the MHC-II and CD64 immune receptors (Singh et al., 2011).
Exosomes from cells infected with the common cell culture
contaminantMycoplasma genus of intracellular parasitic bacteria
have been shown to induce activation of B cells (Quah andO’Neill,
2007), which in turn actively inhibit T cell activation (Yang et al.,
2012a). The activation of immune cells by exosomes released from
M. tuberculosis infected cells has also been demonstrated in vivo in
the absence of infection (Giri et al., 2010). Recently, the laboratory
of one of the authors (RMH) has found that exosomes released
from cells infected with Yersinia pestis induce cytokine release in
naïve cells, and that the treated cells also demonstrate a phenotype
that is similar to infection with Y. pestis. Studies are currently
under way to evaluate the contributions of these exosomes to the
process of pathogenesis.
In the case of B. anthracis infection, exosomes from infected
cells have been shown to contain the lethal toxin (LT) virulence
factor, allowing for the delivery of LT to cells at sites distal to
infection (Abrami et al., 2013). LT consists of two components,
the pore forming protective antigen (PA) and the metalloprotease
lethal factor (LF). After LF is translocated into the cytoplasm
by PA, it is then able to be translocated into ILVs by PA.
This not only provides a location for LF to avoid proteolytic
degradation once inside cells, but also allows for the release of
host-derived exosomes containing LF, which likely contributes
to the persistence and spread of the toxins inside the host
(Abrami et al., 2013). Similarly, exosomes released by cells after
infection with Staphylococcus aureus have been shown to contain
the bacterial pore forming a-toxin, also allowing for delivery of
bacterial virulence factors to cells removed from the immediate
area of infection (Husmann et al., 2009). Cells targeted by the
b-barrel forming a-toxin are able to endocytose areas of their
cell membrane containing the toxin to avoid cell lysis. These
endocytosed vesicles containing the a-toxin are trafficked to the
late endosome where they avoid degradation and are instead
incorporated in exosomes secreted from the host cell. These
secreted exosomes contain both multimeric and monomeric
toxin, both of which could potentially be active when taken up by
naïve cells. Taken together these examples suggest amechanismby
which exosomes containing or presenting PAMPs may contribute
to pathogenesis in the host, potentially at a distant site from the
primary infection.
Protozoan and Helminth-Derived
Exosomes
Protozoan parasites provide multiple examples of pathogen-
derived molecules in exosomes (Aline et al., 2004; Beauvillain
et al., 2009; Schnitzer et al., 2010; Hu et al., 2013). A protease
(GP63 surface protease) of Leishmania mexicana has been
identified on exosomes (Hassani and Olivier, 2013), possibly
suggesting that an enzymatic activity (protease) could be
transmitted to distant sites by this mechanism. T. gondii infection
leads to the inclusion of T. gondii molecules in exosomes (Aline
et al., 2004; Bhatnagar et al., 2007; Beauvillain et al., 2009).
Another protozoan, Cryptosporidium parvum, has recently been
found to strongly induce increased production of exosomes
from both biliary and intestinal epithelium as a result of
infection (Hu et al., 2013), which could then increase the host-
response to any PAMP-molecules that might be included in those
exosomes.
Thus, PAMPs have been identified on exosomes from multiple
viral, bacterial and protozoan pathogens, suggesting that this
might be a more general phenomenon of host-response to
infection (Fleming et al., 2014). Advances in our understanding
of the PAMPs in exosomes could potentially lead to the
development of exosome-based diagnostic tests which could be
readily performed on blood, saliva or urine samples (Wang and
Sun, 2014; Zheng et al., 2014; Huebner et al., 2015), which have
been shown to contain exosomes.
Helminths are parasitic worms including nematodes
(roundworms), tapeworms and flatworms that can cause
serious and chronic infectious diseases such as schistosomiasis
and hookworm. In particular, soil-transmitted helminthiasis,
schistosomiasis, and lymphatic filariasis are considered neglected
tropical diseases (Prichard et al., 2012). It has been estimated that
up to one-third of the three-billion impoverished humans (those
who live on less than $2 US per day) may be infected with one or
more species of helminths (Hotez et al., 2008), and these helminth
infectionsmay also be co-endemic withmalaria andHIV/AIDS in
these populations. According to theWHOonline factsheet N°366,
asmany as 1.5 billion people, or 24% of the globe’s populationmay
be infected with soil-transmitted helminth infections.
Exosomes of endocytic origin and typical exosome size
(30–100 nm) have been identified that contain helminth parasite
proteins. As an example, Marcilla et al. (2012) have demonstrated
the presence of exosomes produced from two trematodes
(Echinostoma caproni and Fasciola hepatica) have shown that these
EVs are “actively released” and demonstrated that they can be
taken up by host cells. The identification of exosomes in these
organisms also explained a phenomenon that had been previously
observed in trematodes, called “secretion of atypical proteins”
(Marcilla et al., 2012). Bernal et al. (2014) recently identified 84
helminth proteins inDicrocoelium dendriticum-derived exosomes
by proteomic analysis, as well as identifying helminth miRNA
within the exosomes, which may be the first report of miRNA
detected in helminth-derived exosomes.
A nematode parasite of the murine gastrointestinal tract,
Heligmosomoides polygyrus, was shown to also produce exosomes
that contain nematode proteins homologous to mammalian
exosome proteins, as well as miRNA, and a nematode homolog
of Argonaute protein (Buck et al., 2014). Furthermore, in this
study, helminth-derived exosomes were found to suppress murine
Type 2 innate immune response, mediated by the nematode
miRNA in the exosomes (Buck et al., 2014). In a related study,
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H. polygyrus-derived exosomes were shown to induce a murine
host response when administered (Marcilla et al., 2014; Montaner
et al., 2014), suggesting that helminth-derived exosomes are
able to significantly modulate the host immune response to the
parasitic infection.
Collectively, these studies suggest an emerging and
important role for helminth-derived exosomes in host-parasite
communication. In addition, proteins and molecules identified
on and in helminth-derived exosomes could provide the basis for
new diagnostic markers for helminth infections. Thus, there is an
increasingly better defined role for EVs including exosomes in the
helminth parasite’s interaction with their hosts. Given that there
are more than 300 species of human-parasitizing helminths, there
will likely be many more examples of EVs being produced from
this group, and demonstrations of their complex interactions with
their eukaryotic hosts (Marcilla et al., 2014).
CONCLUSION
Exosomes, as well as other types of vesicles, are released from the
cell membrane from many cell types in the body after forming in
late endosomes. These vesicles contain proteins, RNA, and lipids
from the host cell. Several databases are available with information
on the thousands of proteins and RNA that have been found in
exosomes including specific markers that can be used to purify
them from supernatant and other bodily fluids including Alix and
CD63.
Among DNA viruses, virally-infected cells can secrete viral
proteins and RNA as well as cellular proteins and miRNA in
exosomes. Recently, researchers have found that EBV miRNA
and functional viral proteins such as LMP1 in exosomes from
infected cells cause cell growth and migration by activating the
PI3K/Akt pathway. Galectin-9 and dUTPase are 2 other viral
proteins that can spread through exosomes and cause apoptosis
and inflammation, respectively. HHV-6 infected cells release
virions enveloped in an exosome, which leadsmany to believe that
the virus spreads through cell-to-cell contact. KSHV exosomes
cause changes in the recipient cell metabolism and aid in latency.
The miRNAs from KSHV exosomes have shown to aid in
tumorigenesis.
RNA viruses such as HIV-1 infected macrophages release an
increased number of exosomes as compared to non-infected cells,
as the virus utilizes the endosomal pathway to spread infection.
Cytokines are incorporated into exosomes from HIV-1 or HTLV-
infected cells that can cause cell migration in recipient cells, and
therefore faster spread of infection. The cytokine expression is
further controlled by either cellular or viral non-coding RNAs
such as HIV-1 TAR. HCV may also utilize the exosomal pathway
to incorporate the nucleocapsid or whole virion into exosomes.
In addition to virally-infected host cells, bacteria, protozoa,
and fungi can all release small vesicles into the extracellular
environment. Bacteria release small vesicles that contain PAMPs,
which signal to uninfected cells to release proinflammatory
cytokines. Protozoan parasites also release exosomes that cause
the release of subsequent cellular exosomes controlling signal
transduction and cell death. Exosomes released from helminthes
and contain helminth proteins can be taken up by host cells.
Exosomes can be used to protect against further infection,
as shown in animal models by activating CD4+ T cells, and
can be modified into effective vaccines. Finally, exosomes can
be modified into biotherapeutics that can easily pass through
the blood–brain barrier. This concept has been shown with
curcumin. Other ongoing studies focus on targeting the exosomes
for specific tissue types by modifying surface proteins. This
method has been proven on DC-derived exosomes targeting the
brain. Collectively, the field of exosome research holds much
promise in not only understanding new and novel conceptual
and fundamental pathways in cellular signal transduction, but
also how infectious diseases utilize this pathway to contribute to
pathogenesis.
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